Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.

<h4>Background</h4>There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).<h4>Methods</h4>The clinical charts of 233 patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shunsuke Tsuzuki, Shotaro Nakanishi, Mitsuyoshi Tamaki, Takuma Oshiro, Jun Miki, Hiroki Yamada, Tatsuya Shimomura, Takahiro Kimura, Nozomu Furuta, Seiichi Saito, Shin Egawa
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/b374a1b5ca054b888c6dc81210d59f89
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/b374a1b5ca054b888c6dc81210d59f89

Ejemplares similares